CATHRYN CANAVA: Open Payments
NPI 1518219476 · WICHITA FALLS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,216 in 14 payments from 10 companies in 2025. Trend: 2023 $137 · 2024 $938 · 2025 $1,216
Food & beverage: $1,216
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 2 | $201 |
| Neurocrine BioSciences, Inc. | 2 | $185 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $174 |
| E.R. Squibb & Sons, L.L.C. | 2 | $164 |
| AstraZeneca Pharmaceuticals LP | 1 | $123 |
| ABBVIE INC. | 1 | $92 |
| Teva Pharmaceuticals USA, Inc. | 1 | $87 |
| Phathom Pharmaceuticals, Inc. | 1 | $78 |
| Eisai Inc. | 1 | $61 |
| Novo Nordisk Inc | 1 | $51 |
Products named: INGREZZA, CAPLYTA, COBENFY, ABILIFY MAINTENA, AIRSUPRA, QULIPTA, AUSTEDO XR, VOQUEZNA.
Industry payments across TX — which companies pay providers there.
